Table 3.

Percutaneous coronary intervention details after propensity match score.

Variable	On-Hours		p-Value	Off-Hours		p-Value
	COVID-19 (−) (n = 877)	COVID-19 (+) (n = 877)		COVID-19 (−) (n = 418)	COVID-19 (+) (n = 418)
Site volume ≥400 PCI in current year	728 (83.0)	782 (89.2)	0.001	344 (82.3)	364 (87.1)	0.07
Radial approach during angiography	756 (86.2)	758 (86.4)	0.9	360 (86.1)	349 (83.5)	0.3
Radial approach during PCI	688 (78.4)	721 (82.2)	0.1	334 (79.9)	318 (76.1)	0.2
PCI operator radial experience (PCI during 2014–2020) (number of all procedures)	1091.2 (685.1)	1143.5 (635.3)	0.1	1059.8 (±709.5)	1063.9 (±675.3)	0.9
PCI operator radial experience (2014–2020) (% of all performed PCI)	81% (±17%)	83% (±18%)	0.1	81% (±16%)	80% (±18%)	0.5
Total amount of contrast (mL)	151.2 (72.3)	150.57 (65.6)	0.8	148.7 (66.9)	149.7 (60.7)	0.8
Total radiation dose (mGy)	743.6 (788)	758.98 (600.7)	0.6	697.0 (727.1)	723.8 (715.9)	0.6
Aspiration thrombectomy during PCI	74 (8.4)	63 (7.2)	0.4	46 (11.0)	49 (11.7)	0.8
Rotational atherectomy during PCI	4 (0.5)	2 (0.2)	0.7	0 (0.0)	2 (0.5)	0.5
P2Y12 inhibitors before and during PCI
Clopidogrel	625 (71.3)	543 (61.9)	0.001	316 (75.6)	299 (71.5)	0.2
Ticagrelor	39 (4.4)	60 (6.8)	0.001	13 (3.1)	9 (2.2)	0.2
Prasugrel	213 (24.3)	274 (31.2)	0.001	89 (21.3)	110 (26.3)	0.2
GPI IIb/IIIa during PCI	708 (80.7)	708 (80.7)	1.0	301 (72.0)	284 (67.9)	0.2
Unfractionated heparin during PCI	838 (95.5)	837 (95.4)		387 (92.6)	390 (93.3)	0.2
Low-molecular-weight heparins during PCI	26 (3.0)	34 (3.9)	0.4	25 (6.0)	21 (5.0)	0.6
Bivalirudin during PCI	13 (1.5)	6 (0.7)	0.2	6 (1.4)	7 (1.7)	1.0

Data are presented as number (percentage) or mean and standard deviation. PCI—percutaneous coronary intervention.